Renal failure, proteinuria and diabetic nephropathy;Insuffisance rénale, protéinurie et néphropathie diabétique

Revue Medicale de Bruxelles

Volumn 24, Issue 4, 2003, Pages

  Collart, F ^a  

^a HIS   (Belgium)

Author keywords

Diabetic nephropathy; Proteinuria; Renal failure

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

CONFERENCE PAPER; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG EFFECT; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FAILURE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DIABETIC NEPHROPATHIES; HUMANS; KIDNEY FAILURE; PROTEINURIA; RECEPTORS, ANGIOTENSIN;

EID: 0141995820     PISSN: 00353639     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (19)

1. Harvey JN: Diabetic nephropathy. New drugs can help to face a growing challenge. BMJ 2002; 325: 59-60
2. Hilgers KF, Mann JFE: ACE inhibitors versus AT1 receptor antagonists in patients with chronic renal disease. J Am Soc Nephrol 2002; 13: 1100-8
3. Rump LC: Advantages of Ang II receptor blockade over ACE inhibition with respect to suppression of sympathetic activity: heartening news for the kidney. Nephrol Dial Transplant 1999; 14: 556-9
4. Cooper ME, Chattington P: Hypertension and diabetes mellitus. In: Mancia G, Chalmers J, Julius S, Saruta T, Weber M, Ferrai A, Wilkinson I, eds. Manual of Hypertension. London, Churchill-Livingstone, 2002: 565-77
5. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR: Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003; 63: 225-32
6. Gaede P, Vedel P, Larsen N, Jensen GVH, Parving HH, Pedersen O: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-93
7. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effet of angiotensin converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-62
8. Gruppo Italiano Di Studi Epidemiologici in Nefrologia (GISEN): Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997; 349: 1857-63
9. Brenner BM, Cooper ME, de Zeeuw D et al: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-9
10. Lewis EJ, Hunsicker LG, Clarke WR et al: Renoprotective effects of angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-60
11. Brenner BM: Retarding the progression of renal disease (Nephrology Forum). Kidney Int 2003; 64: 369-78
12. Buter H, Hemmelder MH, Navis G, de Jong PE, de Zeeuw D: The blunting of antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide. Nephrol Dial Transplant 1998; 13: 1682-5
13. Weir MR, Smith DH, Neutel JM, Bedigian MP: Valsartan alone or with a diuretic or Ace inhibitor as treatment for african american hypertensives: relation to sodium intake. Am J Hypertens 2001; 14: 665-71
14. McLaughlin K, Jardine AG: Angiotensin converting enzyme inhibitors and angiotensin receptor (AT1) antagonists: either or both for primary renal disease. Nephrol Dial Transplant 1999; 14: 25-8
15. Wilkinson-Berka JN, Gibbs NJ, Cooper ME, Skinner SL, Kelly DJ: Renoprotective and antihypertensive effects of combined valsartan and perindopril in progressive diabetic nephropathy in the transgenic (mRen-2)27 rat. Nephrol Dial Transplant 2001; 16: 1343-9
16. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T: Combination treatment of angiotensin II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): A randomized control trial. Lancet 361; 2003: 117-24
17. Campbell R, Sangalli F, Perticucci E et al: Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies. Kidney Int 2003; 63: 1094-103
18. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension: Guidelines Subcommittee. J Hypertens 1999; 17: 151-83
19. Rodicio JL, Alcazar JM: Hypertension in chronic renal failure. European Society of Hypertension Scientific Newsletter: Update on Hypertension Management 2001; 2: 1-2